2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. Na+/K+ ATPase

Na+/K+ ATPase

Sodium potassium pump

Na+/K+ ATPase

Related Products

PDF 0.47 MB

Na+/K+ ATPase (Sodium potassium pump) is a transmembrane protein complex found in all higher eukaryotes acting as a key energy-consuming pump maintaining ionic and osmotic balance in cells. Na+/K+ ATPase is an emerging cancer target that merits further investigation.

The constant activity of the Na+/K+-ATPase (NKA, or Na+ pump) is essential for re-establishing and maintaining this gradient. In cardiac and vascular smooth muscle the principal isoforms of the NKA are α1 and α2 and their physiological role is controlled both by their unique and independent signalling pathways, and their discrete subcellular distribution.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N11690
    Oleandrigenin
    		Inhibitor 98.42%
    Oleandrigenin is a potent cardiotonic steroid. Oleandrigenin shows Na+/K+-ATP-ase inhibiting and cytotoxic activities.
    Oleandrigenin
  • HY-B0137R
    Prilocaine (Standard)
    		Inhibitor
    Prilocaine (Standard) is the analytical standard of Prilocaine. This product is intended for research and analytical applications. Prilocaine, an amino amide, is a Na/K-ATPase inhibitor. Prilocaine has neurotoxic effects.
    Prilocaine (Standard)
  • HY-15718
    Istaroxime
    		Inhibitor
    Istaroxime (PST2744) is a potent inhibitor of Na+,K+-ATPase with IC50 of 0.11 μM.
    Istaroxime
  • HY-B1429R
    Chlorpropamide (Standard)
    		Inhibitor
    Chlorpropamide (Standard) is the analytical standard of Chlorpropamide. This product is intended for research and analytical applications. Chlorpropamide is an oral hypoglycemic agent studied in non-insulin-dependent diabetes mellitus (NIDDM).
    Chlorpropamide (Standard)
  • HY-W779529
    Cerberin
    		Inhibitor 98.0%
    Cerberin is a cardiac glycoside that has been found in C. odollam and has cytotoxic and cardiac modulatory activities. It is cytotoxic to KB and NCI H187 cancer cells (IC50s=1.92 and 1.24 μg/mL).1 Cerberin inhibits Na+/K+-ATPase, increasing intracellular sodium levels and action potential duration in cardiac cells.
    Cerberin
  • HY-B0137AS
    Prilocaine-d7 hydrochloride
    		Inhibitor 98.16%
    Prilocaine-d7 (hydrochloride) is deuterium labeled Prilocaine (hydrochloride). Prilocaine hydrochloride, an amino amide, is a Na, K-ATPase inhibitor. Prilocaine has neurotoxic effects.
    Prilocaine-d<sub>7</sub> hydrochloride
  • HY-109546
    Omeprazole magnesium
    		Inhibitor
    Omeprazole (H 16868) magnesium is an orally active H+,K+-ATPase inhibitor and a proton pump inhibitor. Omeprazole magnesium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole magnesium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole magnesium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole magnesium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole magnesium aslo has neuroprotective and antibacterial effects.
    Omeprazole magnesium
  • HY-N1217
    Stauntosaponin A
    		Inhibitor
    Stauntosaponin A, a steroid glycoside, is a potent inhibitor of Na(+)/K(+)-ATPase with an IC50 value of 21 nM. Stauntosaponin A can be isolated from Carnation and has potential anti-cancer research value.
    Stauntosaponin A
  • HY-126751
    DBM-819
    		Inhibitor
    DBM-819 is a reversible inhibitor of H⁺/K⁺-ATPase (H+/K+-ATPase), with an IC50 value of 5 μM. DBM-819 can reversibly block gastric acid secretion by inhibiting the proton pump in the gastric mucosa. It shows significant protective effects against duodenal ulcers induced by Cysteamine (HY-77591), gastric ulcers induced by Indomethacin (HY-14397), and gastric ulcers induced by Aspirin (HY-14654), with EC50 values of 6, 3.1, and 4 mg/kg respectively. DBM-819 can be used in ulcer prevention research.
    DBM-819
  • HY-108287
    Trithiozine
    		Inhibitor 98.0%
    Trithiozine is an orally active antisecretory and antiulcer agent. Trithiozine can be used for the research of peptic ulcer disease and hypersecretory disorders.
    Trithiozine
  • HY-113410S
    3-Methylglutaric acid-d4
    		Inhibitor
    3-Methylglutaric acid-d4 is the deuterium labeled 3-Methylglutaric acid (HY-113410). 3-Methylglutaric acid is a non-selective inhibitor of mitochondrial function and Na+, K+-ATPase, with an inhibition rate of 30% on rat cortical synaptosomal Na+, K+-ATPase. 3-Methylglutaric acid can induce reactive oxygen species (ROS) generation, thereby causing oxidative damage and inhibiting mitochondrial redox potential and ion pump function of cell membranes. 3-Methylglutaric acid can be used to study the neuropathological mechanisms of metabolic diseases and the role of oxidative stress-mediated neuronal damage in neurodegeneration.
    3-Methylglutaric acid-d<sub>4</sub>
  • HY-B0113AR
    Omeprazole sodium (Standard)
    		Inhibitor
    Omeprazole (sodium) (Standard) is the analytical standard of Omeprazole (sodium). This product is intended for research and analytical applications. Omeprazole sodium (H 16868) is an orally active H+,K+-ATPase inhibitor and a proton pump inhibitor. Omeprazole sodium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole sodium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole sodium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole sodium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole sodium aslo has neuroprotective and antibacterial effects.
    Omeprazole sodium (Standard)
  • HY-W754708
    Ouabagenin
    		Inhibitor
    Ouabagenin is a naturally occurring LXR ligand with LXR selective agonist activity. Ouabagenin acts as an EC 3.6.3.9 (Na(+)/K(+)- transport ATPase) inhibitor.
    Ouabagenin
  • HY-N10097
    Chamigrenol
    		Inhibitor
    Chamigrenol is a Na+/K+-ATPase inhibitor with an IC50 value of 15.9 μg/mL. Chamigrenol shows strong inhibitory activities against Gram-positive and Gram-negative bacteria except Escherichia coli, with MIC values of 50 µg/mL.
    Chamigrenol
  • HY-N17413
    (-)-γ-Cuparenol
    		Inhibitor
    (-)-γ-Cuparenol is a sesquiterpene compound with an IC50 of 23.6 μg/mL against porcine Na+/K+-ATPase. (-)-γ-Cuparenol reduces phytohemagglutinin (PHA)-induced activation of NF-AT and NF-κB in Jurkat cells. (-)-γ-Cuparenol inhibits the growth of Gram-positive bacteria and some Gram-negative bacteria. (-)-γ-Cuparenol exhibits weak inhibitory activity against Candida albicans. (-)-γ-Cuparenol is applicable for research related to immunoregulation, cardiovascular diseases and bacterial infections.
    (-)-γ-Cuparenol
  • HY-113410R
    3-Methylglutaric acid (Standard)
    		Inhibitor
    3-Methylglutaric acid (Standard) is the analytical standard of 3-Methylglutaric acid (HY-113410). This product is intended for research and analytical applications. 3-Methylglutaric acid is a non-selective inhibitor of mitochondrial function and Na+, K+-ATPase, with an inhibition rate of 30% on rat cortical synaptosomal Na+, K+-ATPase. 3-Methylglutaric acid can induce reactive oxygen species (ROS) generation, thereby causing oxidative damage and inhibiting mitochondrial redox potential and ion pump function of cell membranes. 3-Methylglutaric acid can be used to study the neuropathological mechanisms of metabolic diseases and the role of oxidative stress-mediated neuronal damage in neurodegeneration.
    3-Methylglutaric acid (Standard)
  • HY-B0113S1
    Omeprazole-d3-1
    		Inhibitor
    Omeprazole-d3-1 is the deuterium labeled Omeprazole. Omeprazole-1 (H 16868) is an orally active H+,K+-ATPase inhibitor and a proton pump inhibitor. Omeprazole-1 competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole-1 inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole-1 inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole-1 alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole-1 aslo has neuroprotective and antibacterial effects.
    Omeprazole-d<sub>3</sub>-1
  • HY-116444A
    16-HETE
    		Inhibitor
    16-HETE is arachidonic acid metabolite through subterminal hydroxylation by cytochrome P-450. 16-HETE exhibits vasodilatory and PMN inhibitory effects and serves as biomarker for early stages of non-alcoholic fatty liver disease.
    16-HETE
  • HY-B1604A
    Chloroprocaine
    		Inhibitor
    Chloroprocaine (2-Chloroprocaine) is a potent inhibitor of Na,K-ATPase activity with an IC50 of 13 mM. Chloroprocaine blocks peripheral nerve.
    Chloroprocaine
  • HY-W436428
    V-161
    		Inhibitor
    V-161 is the orally active inhibitor for Na+-V-ATPase with an IC50 of 144 nM. V-161 inhibits Enterococcus hirae and Vancomycin-resistant Enterococcus faecium (VRE) under alkaline condition with MIC of 4 µg/mL and 4 µg/mL. V-161 inhibits colonization of VRE in mouse small intestine.
    V-161
Cat. No. Product Name / Synonyms Application Reactivity